Antler Gold Inc. (“Antler” or the “Company”) (TSXV: ANTL) is pleased to announce that it has received the requisite shareholder approval and regulatory approval from the TSX Venture Exchange for the amending agreement dated December 5, 2024 (the “Amending Agreement”) to the agreement with Fortress Asset Management LLC (“Fortress”) dated September 18, 2024 in respect of the Erongo Central Gold Project (the “Project”) in Namibia.
Sona Nanotech Inc. (CSE: SONA, OTCQB: SNANF) (the “Company”, “Sona”) is pleased to announce that the now complete findings from our previously announced pre-clinical breast cancer and melanoma efficacy studies have been published in the peer-reviewed scientific journal, Frontiers in Immunology. This research article includes new follow-up data which provides a comprehensive analysis of the immunity activated by Sona’s Targeted Hyperthermia Therapy (“THT”). The published manuscript titled, “Targeted Intra-tumoral Hyperthermia with Uniquely Biocompatible Gold Nanorods Induces a Strong Immunogenic Cell Death in Two Immunogenically ‘Cold’ Tumors” is available online in electronic form here and will be in print in its upcoming issue of Frontiers in Immunology – Cancer Immunology and Immunotherapy. Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy (“THT”) which uses the Company’s patented, biocompatible gold nanorods (“GNRs”) to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company’s third preclinical efficacy study was conducted in an immunologically ‘cold’ colorectal cancer model (“CT26”), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.
Fortune Bay Corp. (TSXV: FOR) (OTCQB: FTBYF) (FSE: 5QN) (“Fortune Bay” or the “Company”) is pleased to announce plans for a winter 2025 drilling program on the Murmac Uranium Project (“Murmac” or the “Project”) as follow-up to the high-grade uranium intersected during the summer 2024 drill program. The Project is located in northern Saskatchewan near Uranium City, on the northern margin of the Athabasca Basin. The winter program, focused on the Howland Lake North target area, has been approved by the Project’s optionee Aero Energy Limited (TSXV: AERO) (OTC Pink: AAUGF) (FSE: 13L0) (“Aero”) in accordance with the Option Agreement, and is fully-funded.
Antler Gold Inc. (TSXV: ANTL) (“Antler” or the “Company”) is pleased to announce a strategic amendment to its previously announced agreement with Fortress Asset Management LLC (“Fortress”) in respect of the Erongo Central Gold Project (the “Project”) in Namibia. Under the terms of the original agreement dated September 18, 2024 (the “Original Agreement”), Antler granted to Fortress the right to acquire up to a 100% equity interest in the Project in three stages over a three-year period for US$5.5 million. In addition, pursuant to the terms of the Original Agreement, Fortress was also required to incur US$6.0 million of exploration expenditures on the Project. For further details, please see the Company’s News Releases dated May 23, 2024, May 24, 2024, August 22, 2024, and September 18, 2024.
Fortune Bay Corp. (TSXV:FOR, FWB:5QN, OTCQB:FTBYF) (“Fortune Bay” or the “Company”) is pleased to announce commencement of work to further advance its 100% owned Goldfields Gold Project (“Goldfields” or the “Project”), located in northern Saskatchewan. A Preliminary Economic Assessment (“PEA”) completed by Ausenco Engineering Canada Inc., in October 2022 (summarized below), has clearly demonstrated robust economics for Goldfields.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company“, “Sona“) is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, “Metal Nanoparticles and Methods of Making Same“. This patent covers the Company’s proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide (“CTAB”), which typically carries significant cytotoxic and genotoxic risks.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company“, “Sona“) is pleased to announce the issuance of U.S. Patent No. 12117447 by the U.S. Patent and Trademark Office to the Company, entitled, “Metal Nanoparticles and Methods of Making Same“. This patent covers the Company’s proprietary process for manufacturing gold nanorods without the use of the toxic substance, cetyltrimethylammonium bromide (“CTAB”), which typically carries significant cytotoxic and genotoxic risks.
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company” or “Sona”) is pleased to announce that it has granted 25,000 incentive stock options under the Company’s Stock Option Plan (“Option Plan”) to a consultant. Each option is exercisable into one common share at a price of $0.30 per share and will vest at the rate of 25% every six months. The options will expire five years from the date of grant. All other terms and conditions of the options are in accordance with the terms of the Company’s Option Plan.
Fortune Bay Corp. (TSXV:FOR, FSE:5QN, OTCQX: FTBYF) (“Fortune Bay” or the “Company”) is pleased to report high-grade uranium assays in the first batch of analytical results from its 2024 exploration drilling program on the Murmac Uranium Project (“Murmac” or the “Project”), located in northern Saskatchewan near Uranium City. The drilling program was funded by Aero Energy Limited (TSXV: AERO) (OTC Pink: AAUGF) (FSE: 13L0) (“Aero”) under an Option Agreement.